CRISIL Q1 FY27 Results Analysis: Revenue Surges 27.6%, Margins Compress

CompoundingAI Research Updated July 21, 2026 2 min read
Neutral

CRISIL Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 1,075.39 Cr (+27.56% YoY) and PAT growth of +26.08% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 21, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 1,075.39 Cr (+27.56% YoY)
PAT (Q1)Rs. 216.46 Cr (+26.08% YoY)
EBITDA margin28.63% (+31 bps YoY)
EPS (Q1)Rs. 29.60 (+26.17% YoY)
Market capRs. 31,496.47 Cr
CMPRs. 4,309.00

Quarter Snapshot

CRISIL delivered strong 27.6% YoY revenue growth and 26.1% PAT growth, driven by both segments. However, QoQ margins compressed due to cost pressure, and working capital deteriorated sharply as receivables grew faster than revenue. No formal guidance is provided, and the overall picture is mixed with growth offset by operational concerns.

Key Investment Insights

Key Positives

  • Revenue grew 27.6% YoY to Rs.1,075.39 Cr, driven by RAS segment growth of 30.2% YoY and Ratings growth of 21.4% YoY
  • PAT grew 26.1% YoY to Rs.216.46 Cr, tracking revenue growth
  • Ratings revenue growth of 21.4% YoY exceeded system credit growth of ~13%, implying market share gains
  • Subsidiary contribution swung from -Rs.22.57 Cr to +Rs.50.15 Cr YoY, boosting consolidated PAT
  • Interim dividend increased from Rs.9 to Rs.10 per share

Risk Factors

  • EBITDA margin compressed 149 bps QoQ to 28.63%, as total expenses grew 4.0% QoQ vs revenue growth of 1.7% QoQ
  • Other expenses grew 53.9% YoY and 20.3% QoQ, far outpacing revenue, flagged as primary cost concern
  • Trade receivables increased 44.4% in 6 months to Rs.992.29 Cr, much faster than H1 revenue growth of 28.8%, indicating working capital deterioration
  • Ratings segment margin compressed 620 bps QoQ from 50.5% to 44.3%
  • Standalone PAT declined 14.4% YoY due to lower subsidiary dividends and expense growth outpacing revenue
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now